Advertisement

First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation

  • J. Perrin
  • J. Saïas-Magnan
  • F. Broussais
  • R. Bouabdallah
  • C. D’Ercole
  • B. CourbiereEmail author
Letter to the Editor

Dear Editor,

We report the first French live birth after oocyte vitrification-thawing in a cancer survivor, and also the first live birth obtained by oocyte vitrification-thawing in a patient presenting premature ovarian failure (POF) after the treatment of a Hodgkin Lymphoma (HL). The patient gave her written consent for communication about the case.

The overall survival of patients with cancer has improved dramatically. Unfortunately, many treatments affect fertility; fertility preservation (FP) has become an important step in the management of young patients [1, 2]. In female patients, FP techniques indications depends on various parameters; vitrification of mature oocytes has emerged as an established method in the past years [3]. Currently, in the context of FP before cancer treatment, dozens of live births have been published after ovarian cortex cryopreservation and subsequent grafting [4]. Although oocyte vitrification is widely used in assisted reproductive techniques, it is...

Keywords

Hodgkin Lymphoma Antral Follicle Fertility Preservation Premature Ovarian Failure Control Ovarian Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Naessén S, Bergström I, Ljungman P, Landgren B-M. Long-term follow-up of bone density, general and reproductive health in female survivors after treatment for haematological malignancies. Eur J Haematol. 2014;93(2):137–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Cobo A, Garcia-Velasco JA, Domingo J, Remohí J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013;99(6):1485–95.CrossRefPubMedGoogle Scholar
  3. 3.
    De Vos M, Smitz J, Woodruff TK. Fertility preservation in women with cancer. Lancet Lond Engl. 2014;384(9950):1302–10.CrossRefGoogle Scholar
  4. 4.
    Donnez J, Dolmans M-M. Ovarian tissue freezing: current status. Curr Opin Obstet Gynecol. 2015;27(3):222–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMedGoogle Scholar
  7. 7.
    de Braga DP AF, de Figueroa R CS, Ferreira RC, Pasqualotto FF, Iaconelli A, Borges E. Contribution of in-vitro maturation in ovarian stimulation cycles of poor-responder patients. Reprod Biomed Online. 2010;20(3):335–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod Oxf Engl. 2011; 26(6):1270–83.Google Scholar
  9. 9.
    Yang D, Brown SE, Nguyen K, Reddy V, Brubaker C, Winslow KL. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil Steril. 2007;87(6):1469. e1–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Dittrich R, Lotz L, Keck G, Hoffmann I, Mueller A, Beckmann MW, et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil Steril. 2012;97(2):387–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(10):2052–60.CrossRefGoogle Scholar
  12. 12.
    Kim MK, Lee DR, Han JE, Kim YS, Lee WS, Won HJ, et al. Live birth with vitrified-warmed oocytes of a chronic myeloid leukemia patient nine years after allogenic bone marrow transplantation. J Assist Reprod Genet. 2011;28(12):1167–70.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Garcia-Velasco JA, Domingo J, Cobo A, Martínez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99(7):1994–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Alvarez M, Solé M, Devesa M, Fábregas R, Boada M, Tur R, et al. Live birth using vitrified-warmed oocytes in invasive ovarian cancer: case report and literature review. Reprod Biomed Online. 2014;28(6):663–8.CrossRefPubMedGoogle Scholar
  15. 15.
    da Motta ELA, Bonavita M, Alegretti JR, Chehin M, Serafini P. Live birth after 6 years of oocyte vitrification in a survivor with breast cancer. J Assist Reprod Genet. 2014;31(10):1397–400.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Martinez M, Rabadan S, Domingo J, Cobo A, Pellicer A, Garcia-Velasco JA. Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. Reprod Biomed Online. 2014;29(6):722–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • J. Perrin
    • 1
    • 2
    • 3
  • J. Saïas-Magnan
    • 1
    • 3
  • F. Broussais
    • 4
  • R. Bouabdallah
    • 4
  • C. D’Ercole
    • 1
  • B. Courbiere
    • 1
    • 2
    • 3
    Email author
  1. 1.CECOS – Centre Clinico-Biologique d’Assistance Médicale à la Procréation, Pole Femmes Parents Enfants, AP-HM La ConceptionMarseilleFrance
  2. 2.Aix Marseille Université, CNRS, IRDAvignon Université, IMBE UMR 7263MarseilleFrance
  3. 3.Plateforme Régionale « Cancer & Fertilité », Réseau Régional de Cancérologie ONCOPACA CorseMarseilleFrance
  4. 4.Cancer Center Institut J. Paoli-Calmettes, Aix Marseille UniversitéMarseilleFrance

Personalised recommendations